Identification and analyses of cancer stem-like cells in large cell neuroendocrine carcinoma of the lung

肺大细胞神经内分泌癌中癌症干细胞样细胞的鉴定和分析

• 批准号: 24791481
• 负责人: HISHIDA Tomoyuki
• 金额: $ 2万
• 依托单位: National Center of Neurology and Psychiatry
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2012
• 资助国家: 日本
• 起止时间: 2012-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24791481/
• 关键词: 肺高悪性度神経内分泌癌; がん幹細胞; 小細胞癌; 大細胞神経内分泌癌; 臨床病理学的研究

We evaluated the expression and clinical significance of cancer stem-like cells (CSLC) markers in high-grade neuroendocrine carcinoma (HGNEC) of the lung, comprising small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) in order to develop new treatment strategy. The expression of putative CSLC markers were examined immunohistochemically by using resected tumor specimens. HGNEC of the lung had various range of positive expression of CSLC markers. Among explored CSLC markers, ALDH1 expression was related to patient outcomes. ALDH1-positive HGNEC had significantly poorer survival than those with ALDH1- negative HGNEC. Multivariate analysis also revealed positive ALDH1 expression as an independent unfavorable prognostic factors. ALDH1-positive tumor cells were frequently observed even in micro lymph node metastases. These induced that targeting for ALDH1-positive tumor cells might be a future treatment strategy in HGNEC of the lung.

我们评估了癌症干细胞样细胞（CSLC）标记物在肺高级别神经内分泌癌（HGNEC）中的表达及其临床意义，包括小细胞肺癌（SCLC）和大细胞神经内分泌癌（LCNEC），以开发新的治疗策略。采用免疫组化方法检测CSLC标志物的表达。肺HGNEC有不同范围的CSLC标志物阳性表达。在研究的CSLC标志物中，ALDH1表达与患者结局相关。ALDH1阳性HGNEC的存活率显著低于ALDH1阴性HGNEC。多因素分析显示ALDH 1阳性表达是独立的预后不良因素。ALDH1阳性肿瘤细胞即使在微小淋巴结转移中也经常观察到。这些提示靶向ALDH 1阳性肿瘤细胞可能是肺HGNEC未来的治疗策略。

项目成果

胸腺癌の臨床像 当院での５０例の経験から

胸腺癌的临床特点：基于我院50例的经验

• 发表时间: 2012
• 作者: 清水恵;菱田智之ほか
• 通讯作者: 菱田智之ほか

SURVIVAL AFTER BILATERAL LUNG RESECTIONS OF PRIMARY LUNG CANCER WITH CONTRALATERAL SATELLITE NODULES: SHOULD A SMALL NUMBER OF CONTRALATERAL NODULES BE TREATED AS M1A DISEASE?

伴对侧卫星结节的原发性肺癌双侧肺切除后的生存率：少量对侧结节是否应作为 M1A 疾病治疗？

• 发表时间: 2012
• 作者: Tomoyuki Hishida;et al.
• 通讯作者: et al.

Surgical Outcomes after Initial Surgery for Clinical Single-station N2 Non-small-cell Lung Cancer

• DOI: 10.1093/jjco/hyt164
• 发表时间: 2014-01-01
• 期刊: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
• 影响因子: 2.4
• 作者: Hishida, Tomoyuki;Yoshida, Junji;Nagai, Kanji
• 通讯作者: Nagai, Kanji

大細胞神経内分泌癌の予後因子 混合型大細胞神経内分泌癌を中心として

大细胞神经内分泌癌的预后因素 聚焦混合性大细胞神经内分泌癌

• 发表时间: 2013
• 作者: 三好智裕;菱田智之;石井源一郎;仁保誠治;荒牧直;松村勇輝;青景圭樹;吉田純司;大江裕一郎;永井完治
• 通讯作者: 永井完治

対側肺に結節を認める原発性肺癌の手術成績 ―数が限定的な対側肺副腫瘍結節はclinical M1a か？―

对侧肺有结节的原发性肺癌的手术结果 - 对侧肺副肿瘤结节数量有限是否为临床 M1a？

• 发表时间: 2012
• 作者: 清水恵;菱田智之ほか;Toshiki Endo;井原 哲，玉田一敬;菱田智之ほか
• 通讯作者: 菱田智之ほか